Therapy for Older AML Patients: The Role of Novel Agents and Allogeneic Stem Cell Transplant

Publisher： Cambridge Scholars Publishing in association with GSE Research

ISSN： 1540-1405

Source： Journal of the National Comprehensive Cancer Network (JNCCN), Vol.6, Iss.10, 2008-11, pp. : 1017-1025

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents

Current Cancer Drug Targets, Vol. 13, Iss. 6, 2013-07 ,pp. : 661-669

Bentham Science Publishers

Access to resources Recommend Favorite

Immunosuppressive Therapy in Older Cardiac Transplant Patients

By Arezu Zejnab Aliabadi Andreas Oliver Zuckermann Grimm Michael

Drugs & Aging, Vol. 24, Iss. 11, 2007-01 ,pp. : 913-932

Adis International

Access to resources Recommend Favorite

Novel approaches to lupus drug discovery using stem cell therapy. Role of mesenchymal-stem-cell-secreted factors

By Figueroa Fernando E Cuenca Moreno Jimena La Cava Antonio

Expert Opinion on Drug Discovery, Vol. 9, Iss. 5, 2014-05 ,pp. : 555-566

Informa Healthcare

Access to resources Recommend Favorite

New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients

By Zuccotti Gianna Strasfeld Lynne Weinstock David M

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 10, 2005-08 ,pp. : 1669-1679

Informa Healthcare

Access to resources Recommend Favorite

Substantial costs for stem cell transplantation in AML, ALL

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 385, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite